Results 61 to 70 of about 7,402 (202)

Evaluation of Drug–Drug Interaction Potential Between the Oral Antibiotic Zoliflodacin and the CYP3A4 Inhibitor Itraconazole: A Phase 1 Study in Healthy Participants

Clinical and Translational Science, Volume 19, Issue 3, March 2026.
ABSTRACT Zoliflodacin is a first‐in‐class oral spiropyrimidinetrione antibiotic being developed for patients with uncomplicated gonorrhea, including those infected with multidrug‐resistant strains. Because zoliflodacin is metabolized by cytochrome P450 3A4 (CYP3A4), concomitant administration with a CYP3A inhibitor has the potential to increase ...
Alison Luckey, Kajal B. Larson, Noha Rayad, Markus Heep, Sophie Delhomme, Gabrielle Kornmann, John P. Mueller, John P. O'Donnell, Seamus O'Brien, Rainard Fuhr, Jean‐Yves Gillon   +10 more
wiley   +1 more source

Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection

HIV/AIDS: Research and Palliative Care, 2016
Rustin D Crutchley,1 Rakesh C Guduru,2 Amy M Cheng1 1Department of Pharmacy Practice and Translational Research, College of Pharmacy, University of Houston, 2CompanionDX, Houston, TX, USA Abstract: Atazanavir/cobicistat (ATV/c) and darunavir/cobicistat (
Crutchley RD, Guduru RC, Cheng AM,
doaj  

Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir [PDF]

, 2016
OBJECTIVE: Atazanavir (ATV) and lopinavir (LPV) have been associated with kidney disease progression in HIV positive patients, with no data reported for darunavir (DRV).
Chadwick, D, Hamzah, L, Jones, R, Jose, S, Nelson, M, Phillips, A, Post, FA, Sabin, CA, Trevelion, R, Williams, DI   +9 more
core   +2 more sources

Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1-Infected Patients: Week 48 Results [PDF]

, 2017
Background. Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro. Methods. An international, randomized, double-blind, double-dummy, active-controlled trial was conducted to evaluate the efficacy and safety of COBI versus ...
Andrade-Villanueva, Jaime, Antunes, Francisco, Arastéh, Keikawus, Callebaut, Christian, Cheng, Andrew K., Chetchotisakd, Ploenchan, DeJesus, Edwin, Fehr, Jan, Gallant, Joel E., Koenig, Ellen, Liu, Yapei, Moyle, Graeme, Rhee, Martin S., Rizzardini, Giuliano, Szwarcberg, Javier, Zhong, Lijie   +15 more
core  

Polypharmacy in HIV: Rethinking what counts and why it matters

HIV Medicine, Volume 27, Issue 2, Page 186-199, February 2026.
Abstract Polypharmacy, the concurrent use of multiple medications, presents a growing challenge in HIV care as people living with HIV age and experience earlier onset of age‐related co‐morbidities. However, how polypharmacy is defined and assessed in HIV research remains inconsistent.
Luxsena Sukumaran, Alan Winston, Catia Marzolini, Saye Khoo, Marta Boffito, Nadia Naous, Caroline A. Sabin   +6 more
wiley   +1 more source

HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study

AIDS Research and Therapy, 2017
Background As a simplification strategy for treatment-experienced HIV-infected patients who have achieved virologic suppression on a multi-drug, multi-class antiretroviral regimen, the aim of this study was to evaluate the safety, efficacy, and ...
Marianne Harris, Bruce Ganase, Birgit Watson, P. Richard Harrigan, Julio S. G. Montaner, Mark W. Hull   +5 more
doaj   +1 more source

Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes [PDF]

, 2014
To evaluate the replication capacity and phenotypic susceptibility to dolutegravir and raltegravir of wild-type and raltegravir-resistant HIV-1 strains in several cellular ...
Calvez, V, Ceccherini-Silberstein, F, Cortese, Mf, di Santo, F, Fabeni, L, Fedele, V, Malet, I, Marcelin, A-, Perno, CF, Pollicita, M, Surdo, M, Svicher, V   +11 more
core   +1 more source

People living with HIV on modern antiretrovirals do not display a pro‐atherogenic lipid profile and have similar body composition compared to healthy controls

HIV Medicine, Volume 27, Issue 1, Page 86-95, January 2026.
Abstract Objectives Alterations in lipids and apolipoproteins contribute to cardiovascular disease (CVD) and are common in people with HIV. The aim of our study was to compare lipid profiles and body composition between people with and without HIV and to explore whether any associations with HIV could be explained by socio‐demographic, clinical ...
S. Savinelli, A. Heeney, W. Tinago, A. A. Garcia Leon, P. McGettrick, A. G. Cotter, I. Walsh, M. Fitzgibbon, C. A. Sabin, P. W. G. Mallon, E. R. Feeney, on behalf of the HIV UPBEAT study group   +11 more
wiley   +1 more source

Systematic Literature Review and Meta-Analysis of Renal Function in Human Immunodeficiency Virus (HIV)-Infected Patients Treated with Atazanavir (ATV)-Based Regimens.

PLoS ONE, 2015
Some HIV antiretroviral therapies (ART) have been associated with renal toxicities, which become of increasing concern as HIV-infected patients age and develop comorbidities.
Sandrine Cure, Florence Bianic, Caroline Espinas, Helene Hardy, Lisa Rosenblatt, Timothy Juday   +5 more
doaj   +1 more source

Dosing antiretroviral medication when crossing time zones: a review [PDF]

, 2016
International tourism continues to increase worldwide, and people living with HIV and their clinicians are increasingly confronted with the problem of how to dose antiretroviral therapy during transmeridian air travel across time zones.
Boffito, Marta, Khoo, Saye, Lewis, Joseph M, Volny-Anne, Alain, Waitt, Catriona   +4 more
core   +1 more source